Cullinan Oncology

97 articles about Cullinan Oncology

• 

  Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement

  4/17/2024

  Cullinan Oncology, now renamed Cullinan Therapeutics, is riding the growing wave of interest in autoimmune disorders by refocusing its bispecific T cell-engager CLN-978 for systemic lupus erythematosus.

• Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

  4/16/2024

  Cullinan Therapeutics, Inc. announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant.

• Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

  3/14/2024

  Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2023.

• Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

  3/1/2024

  Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, announced the U.S. Food and Drug Administration has cleared its Investigational New Drug application for CLN-619 in relapsed/refractory multiple myeloma.

• Cullinan Oncology to Participate in Upcoming March 2024 Investor Conferences

  2/27/2024

  Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, announced its participation in the following upcoming investor conferences.

• Adimab Provides 2023 Update on Clinical Pipeline

  1/9/2024

  Adimab, LLC today announced that 12 new partner programs entered clinical development in 2023.

• Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  12/18/2023

  Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed’s presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST).

• Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

  11/8/2023

  Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2023.

• Cullinan Oncology to Participate in Upcoming Investor Conferences - October 30, 2023

  10/30/2023

  Cullinan Oncology, Inc. today announced its participation in the following upcoming investor conferences.

• Cullinan Oncology to Participate in Upcoming Investor Conferences - September 6, 2023

  9/6/2023

  Cullinan Oncology, Inc. today announced its participation in the following upcoming investor conferences.

• Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

  8/10/2023

  Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2023.

• Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

  8/9/2023

  Cullinan Oncology, Inc. today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CLN-978 for the treatment of relapsed/refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL).

• Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

  5/25/2023

  Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, announced first monotherapy clinical data from its Phase 1 study of CLN-619 in patients with advanced solid tumors.

• Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

  5/11/2023

  Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, reported on recent and upcoming business highlights and announced its financial results for the first quarter ended March 31, 2023.

• Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

  4/26/2023

  Cullinan Oncology, Inc. today announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced solid tumors will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 2-6.

• Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

  4/20/2023

  Cullinan Oncology, Inc. today announced that its President and Chief Executive Officer, Nadim Ahmed, will participate in a fireside chat at the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 2:30 PM EDT.

• Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

  3/27/2023

  Cullinan Oncology, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-617.

• Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

  3/14/2023

  Cullinan Oncology, Inc., (Nasdaq: CGEM) (“Cullinan Oncology”) today announced that posters of preclinical data highlighting the therapeutic potential of two assets, CLN-619 and CLN-617, will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, Florida, April 14-17, 2023.

• Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/9/2023

  Cullinan Oncology, Inc. today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2022.

• Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

  2/27/2023

  Cullinan Oncology, Inc. today announced that its President and Chief Executive Officer, Nadim Ahmed, will present at Cowen’s 43rd Annual Health Care Conference on March 6, 2023 at 11:10 AM EST.